VIENNA — In this exclusive video from the International Liver Congress 2019, Patrick T. Horn, MD, PhD, chief medical officer of Albireo Pharmaceuticals, provides an update on A4250, an ileal bile acid transporter inhibitor for the treatment of pediatric cholestatic diseases.
“Albireo has the potential to bring forward some products that can be life-altering for these patients with pediatric cholestatic disease,” Horn told Healio Gastroenterology and Liver Disease. “Across the spectrum of pediatric cholestatic liver diseases, A4250 is able to lower bile acids and show

Source link